{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T06:37:31Z","timestamp":1781073451940,"version":"3.54.1"},"reference-count":126,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology - Research and Practice"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.prp.2025.155985","type":"journal-article","created":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T06:53:01Z","timestamp":1745304781000},"page":"155985","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["The critical role of GLP-1 signaling pathways in the pathology of Parkinson's disease and diabetes"],"prefix":"10.1016","volume":"270","author":[{"given":"Jinhao","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yichen","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8535-0184","authenticated-orcid":false,"given":"Cunming","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.prp.2025.155985_bib1","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","article-title":"Glucagon-like peptide-1 receptor: mechanisms and advances in therapy","volume":"9","author":"Zheng","year":"2024","journal-title":"Signal Transduct. Target Ther."},{"key":"10.1016\/j.prp.2025.155985_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art","volume":"46","author":"Nauck","year":"2021","journal-title":"Mol. Metab."},{"issue":"8","key":"10.1016\/j.prp.2025.155985_bib3","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.7150\/ijbs.59965","article-title":"GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential","volume":"17","author":"Ma","year":"2021","journal-title":"Int J. Biol. Sci."},{"key":"10.1016\/j.prp.2025.155985_bib4","doi-asserted-by":"crossref","first-page":"1462240","DOI":"10.3389\/fneur.2024.1462240","article-title":"Neuroprotective effects of GLP-1 class drugs in Parkinson's disease","volume":"15","author":"Lv","year":"2024","journal-title":"Front Neurol."},{"issue":"3","key":"10.1016\/j.prp.2025.155985_bib5","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1038\/s41591-024-03412-w","article-title":"Mapping the effectiveness and risks of GLP-1 receptor agonists","volume":"31","author":"Xie","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.prp.2025.155985_bib6","doi-asserted-by":"crossref","DOI":"10.1007\/s10557-025-07670-9","article-title":"Therapeutic potential of GLP-1 receptor agonists in diabetes and cardiovascular disease: mechanisms and clinical implications","author":"Zhang","year":"2025","journal-title":"Cardiovasc Drugs Ther."},{"issue":"3","key":"10.1016\/j.prp.2025.155985_bib7","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s005920050116","article-title":"Glucagon-like peptide 1 (GLP-1): a potent gut hormone with a possible therapeutic perspective","volume":"35","author":"Nauck","year":"1998","journal-title":"Acta Diabetol."},{"issue":"4","key":"10.1016\/j.prp.2025.155985_bib8","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/bph.15462","article-title":"Glucagon-like peptide-1 (GLP-1) receptor agonists and their cardiovascular benefits-The role of the GLP-1 receptor","volume":"179","author":"Helmst\u00e4dter","year":"2022","journal-title":"Br. J. Pharm."},{"key":"10.1016\/j.prp.2025.155985_bib9","doi-asserted-by":"crossref","DOI":"10.1177\/2042018821997320","article-title":"GLP-1 receptor agonists: an updated review of head-to-head clinical studies","volume":"12","author":"Trujillo","year":"2021","journal-title":"Ther. Adv. Endocrinol. Metab."},{"key":"10.1016\/j.prp.2025.155985_bib10","doi-asserted-by":"crossref","first-page":"665","DOI":"10.2147\/DDDT.S348055","article-title":"The role of glucagon-like peptide-1 receptor agonists (GLP-1 RA) in diabetes-related neurodegenerative diseases","volume":"16","author":"Cheng","year":"2022","journal-title":"Drug Des. Dev. Ther."},{"issue":"3","key":"10.1016\/j.prp.2025.155985_bib11","doi-asserted-by":"crossref","first-page":"285","DOI":"10.3727\/000000007783464731","article-title":"Blood-brain barrier pathology in Alzheimer's and Parkinson's disease: implications for drug therapy","volume":"16","author":"Desai","year":"2007","journal-title":"Cell Transpl."},{"issue":"1","key":"10.1016\/j.prp.2025.155985_bib12","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41392-023-01481-w","article-title":"The blood-brain barrier: structure, regulation, and drug delivery","volume":"8","author":"Wu","year":"2023","journal-title":"Signal Transduct. Target Ther."},{"issue":"S8 1","key":"10.1016\/j.prp.2025.155985_bib13","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/01.JAA.0000669456.13763.bd","article-title":"Long-acting GLP-1RAs: an overview of efficacy, safety, and their role in type 2 diabetes management","volume":"33","author":"Chun","year":"2020","journal-title":"Jaapa"},{"key":"10.1016\/j.prp.2025.155985_bib14","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.peptides.2018.07.001","article-title":"GLP-1 receptor agonists stimulate ANGPTL8 production through the PI3K\/Akt pathway in a GLP-1 receptor-dependent manner","volume":"106","author":"Liu","year":"2018","journal-title":"Peptides"},{"issue":"Pt 3","key":"10.1016\/j.prp.2025.155985_bib15","article-title":"Neuroprotective effects of GLP-1 receptor agonists in neurodegenerative disorders: a large-scale propensity-matched cohort study","volume":"143","author":"Siddeeque","year":"2024","journal-title":"Int Immunopharmacol."},{"key":"10.1016\/j.prp.2025.155985_bib16","doi-asserted-by":"crossref","DOI":"10.1002\/mds.29992","article-title":"Glucagon-like peptide-1 receptor agonists and risk of Parkinson's disease in patients with type 2 diabetes: a population-based cohort study","author":"Tang","year":"2024","journal-title":"Mov. Disord."},{"key":"10.1016\/j.prp.2025.155985_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106550","article-title":"Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: implications for neurodegenerative disease treatment","volume":"186","author":"Kopp","year":"2022","journal-title":"Pharm. Res"},{"issue":"1","key":"10.1016\/j.prp.2025.155985_bib18","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13099-021-00446-0","article-title":"Gut microbiota influence in type 2 diabetes mellitus (T2DM)","volume":"13","author":"Cunningham","year":"2021","journal-title":"Gut Pathog."},{"key":"10.1016\/j.prp.2025.155985_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/S1569-1993(24)01512-1","article-title":"Glucagon-like-peptide-1 agonist therapy in adults with cystic fibrosis","author":"Park","year":"2024","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.prp.2025.155985_bib20","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.molmet.2019.09.010","article-title":"Glucagon-like peptide 1 (GLP-1)","volume":"30","author":"M\u00fcller","year":"2019","journal-title":"Mol. Metab."},{"issue":"3","key":"10.1016\/j.prp.2025.155985_bib21","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.molcel.2020.09.020","article-title":"Differential GLP-1R binding and activation by peptide and non-peptide agonists","volume":"80","author":"Zhang","year":"2020","journal-title":"Mol. Cell"},{"issue":"1","key":"10.1016\/j.prp.2025.155985_bib22","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/nchembio.478","article-title":"Signaling diversity of PKA achieved via a Ca2+\u2009-cAMP-PKA oscillatory circuit","volume":"7","author":"Ni","year":"2011","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.prp.2025.155985_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114531","article-title":"CREB nuclear transcription activity as a targeting factor in the treatment of diabetes and diabetes complications","volume":"188","author":"Benchoula","year":"2021","journal-title":"Biochem. Pharm."},{"issue":"1","key":"10.1016\/j.prp.2025.155985_bib24","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.neuron.2014.03.016","article-title":"Neuronal voltage-gated calcium channels: structure, function, and dysfunction","volume":"82","author":"Simms","year":"2014","journal-title":"Neuron"},{"key":"10.1016\/j.prp.2025.155985_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2024.116119","article-title":"The role of G protein-coupled receptor kinases in GLP-1R \u03b2-arrestin recruitment and internalisation","volume":"222","author":"McNeill","year":"2024","journal-title":"Biochem Pharm."},{"issue":"1","key":"10.1016\/j.prp.2025.155985_bib26","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41419-023-05569-7","article-title":"Extracellular signal-Regulated Kinase 5 (ERK5) is required for the Yes-associated protein (YAP) co-transcriptional activity","volume":"14","author":"Ippolito","year":"2023","journal-title":"Cell Death Dis."},{"issue":"5","key":"10.1016\/j.prp.2025.155985_bib27","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1016\/j.apsb.2021.12.022","article-title":"Development of small molecule extracellular signal-regulated kinases (ERKs) inhibitors for cancer therapy","volume":"12","author":"Pan","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"issue":"2","key":"10.1016\/j.prp.2025.155985_bib28","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ceca.2015.04.003","article-title":"Plant phospholipase C family: regulation and functional role in lipid signaling","volume":"58","author":"Singh","year":"2015","journal-title":"Cell Calcium"},{"key":"10.1016\/j.prp.2025.155985_bib29","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.neuint.2019.04.010","article-title":"GLP-1: molecular mechanisms and outcomes of a complex signaling system","volume":"128","author":"Smith","year":"2019","journal-title":"Neurochem. Int."},{"issue":"8","key":"10.1016\/j.prp.2025.155985_bib30","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.molmet.2014.08.001","article-title":"CREB mediates the insulinotropic and anti-apoptotic effects of GLP-1 signaling in adult mouse \u03b2-cells","volume":"3","author":"Shin","year":"2014","journal-title":"Mol. Metab."},{"key":"10.1016\/j.prp.2025.155985_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.mce.2020.110921","article-title":"GLP-1 promotes osteogenic differentiation of human ADSCs via the Wnt\/GSK-3\u03b2\/\u03b2-catenin pathway","volume":"515","author":"Li","year":"2020","journal-title":"Mol. Cell Endocrinol."},{"key":"10.1016\/j.prp.2025.155985_bib32","doi-asserted-by":"crossref","first-page":"1125693","DOI":"10.3389\/fendo.2023.1125693","article-title":"Cardiovascular-renal protective effect and molecular mechanism of finerenone in type 2 diabetic mellitus","volume":"14","author":"Lv","year":"2023","journal-title":"Front Endocrinol."},{"issue":"3","key":"10.1016\/j.prp.2025.155985_bib33","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1002\/j.2040-4603.2020.tb00136.x","article-title":"Role of skeletal muscle in insulin resistance and glucose uptake","volume":"10","author":"Merz","year":"2020","journal-title":"Compr. Physiol."},{"issue":"2","key":"10.1016\/j.prp.2025.155985_bib34","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/s41401-021-00647-y","article-title":"The glycolytic process in endothelial cells and its implications","volume":"43","author":"Leung","year":"2022","journal-title":"Acta Pharm. Sin."},{"issue":"6","key":"10.1016\/j.prp.2025.155985_bib35","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1053\/j.gastro.2007.03.054","article-title":"Biology of incretins: GLP-1 and GIP","volume":"132","author":"Baggio","year":"2007","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.prp.2025.155985_bib36","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/j.jmb.2019.08.009","article-title":"New insights into beta-cell GLP-1 REceptor and cAMP signaling","volume":"432","author":"Tomas","year":"2020","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.prp.2025.155985_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2022.170749","article-title":"GLP-1 and GIP receptor signaling in beta cells - a review of receptor interactions and co-stimulation","volume":"151","author":"Mayendraraj","year":"2022","journal-title":"Peptides"},{"issue":"2","key":"10.1016\/j.prp.2025.155985_bib38","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.pbiomolbio.2011.07.010","article-title":"Two incretin hormones GLP-1 and GIP: comparison of their actions in insulin secretion and \u03b2 cell preservation","volume":"107","author":"Yabe","year":"2011","journal-title":"Prog. Biophys. Mol. Biol."},{"issue":"2","key":"10.1016\/j.prp.2025.155985_bib39","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1016\/S1262-3636(08)73398-6","article-title":"GLP-1 receptor signaling: effects on pancreatic beta-cell proliferation and survival","volume":"34","author":"Buteau","year":"2008","journal-title":"Diabetes Metab."},{"issue":"12","key":"10.1016\/j.prp.2025.155985_bib40","doi-asserted-by":"crossref","first-page":"5145","DOI":"10.1210\/en.2003-1147","article-title":"Glucagon-like peptide-1 and the islet beta-cell: augmentation of cell proliferation and inhibition of apoptosis","volume":"144","author":"Drucker","year":"2003","journal-title":"Endocrinology"},{"issue":"1","key":"10.1016\/j.prp.2025.155985_bib41","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s10020-024-00808-9","article-title":"Endoplasmic reticulum stress and therapeutic strategies in metabolic, neurodegenerative diseases and cancer","volume":"30","author":"Yuan","year":"2024","journal-title":"Mol. Med."},{"key":"10.1016\/j.prp.2025.155985_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuint.2019.104583","article-title":"Mechanism of the neuroprotective effect of GLP-1 in a rat model of Parkinson's with pre-existing diabetes","volume":"131","author":"Elbassuoni","year":"2019","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.prp.2025.155985_bib43","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.npep.2018.07.003","article-title":"Neuroprotective effects of the novel GLP-1 long acting analogue semaglutide in the MPTP Parkinson's disease mouse model","volume":"71","author":"Zhang","year":"2018","journal-title":"Neuropeptides"},{"issue":"11","key":"10.1016\/j.prp.2025.155985_bib44","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1016\/j.bbamcr.2011.03.010","article-title":"Akt, FoxO and regulation of apoptosis","volume":"1813","author":"Zhang","year":"2011","journal-title":"Biochim Biophys. Acta"},{"issue":"1","key":"10.1016\/j.prp.2025.155985_bib45","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/s41420-024-01953-0","article-title":"PGC-1a mediated mitochondrial biogenesis promotes recovery and survival of neuronal cells from cellular degeneration","volume":"10","author":"You","year":"2024","journal-title":"Cell Death Discov."},{"issue":"6","key":"10.1016\/j.prp.2025.155985_bib46","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24065487","article-title":"Neuroinflammation and oxidative stress in the pathogenesis of autism spectrum disorder","volume":"24","author":"Usui","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.prp.2025.155985_bib47","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s10787-019-00580-x","article-title":"Activation of microglia and astrocytes: a roadway to neuroinflammation and Alzheimer's disease","volume":"27","author":"Kaur","year":"2019","journal-title":"Inflammopharmacology"},{"issue":"17","key":"10.1016\/j.prp.2025.155985_bib48","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23179583","article-title":"Anti-inflammatory effects of GLP-1 receptor activation in the brain in neurodegenerative diseases","volume":"23","author":"Diz-Chaves","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"13","key":"10.1016\/j.prp.2025.155985_bib49","doi-asserted-by":"crossref","DOI":"10.1128\/MCB.00099-20","article-title":"The molecular mechanisms regulating the KEAP1-NRF2 pathway","volume":"40","author":"Baird","year":"2020","journal-title":"Mol. Cell Biol."},{"issue":"14","key":"10.1016\/j.prp.2025.155985_bib50","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.2174\/1381612824666180327165604","article-title":"Signaling pathways in inflammation and anti-inflammatory therapies","volume":"24","author":"Yeung","year":"2018","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.prp.2025.155985_bib51","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.neures.2023.02.001","article-title":"Astrocytes and brain-derived neurotrophic factor (BDNF)","volume":"197","author":"Albini","year":"2023","journal-title":"Neurosci. Res."},{"key":"10.1016\/j.prp.2025.155985_bib52","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s12933-014-0142-7","article-title":"Cardiovascular effects of glucagon-like peptide 1 (GLP-1) receptor agonists","volume":"13","author":"Saraiva","year":"2014","journal-title":"Cardiovasc Diabetol."},{"key":"10.1016\/j.prp.2025.155985_bib53","doi-asserted-by":"crossref","first-page":"26859","DOI":"10.1038\/srep26859","article-title":"The neuroprotection of liraglutide against ischaemia-induced apoptosis through the activation of the PI3K\/AKT and MAPK pathways","volume":"6","author":"Zhu","year":"2016","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.prp.2025.155985_bib54","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/s41380-021-01253-4","article-title":"How changes in dopamine D2 receptor levels alter striatal circuit function and motivation","volume":"27","author":"Simpson","year":"2022","journal-title":"Mol. Psychiatry"},{"issue":"4","key":"10.1016\/j.prp.2025.155985_bib55","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab."},{"issue":"5","key":"10.1016\/j.prp.2025.155985_bib56","doi-asserted-by":"crossref","DOI":"10.1111\/cns.14763","article-title":"Autophagy-associated non-coding RNAs: unraveling their impact on Parkinson's disease pathogenesis","volume":"30","author":"Hussain","year":"2024","journal-title":"CNS Neurosci. Ther."},{"issue":"6","key":"10.1016\/j.prp.2025.155985_bib57","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s12576-016-0445-4","article-title":"Neuronal circuits and physiological roles of the basal ganglia in terms of transmitters, receptors and related disorders","volume":"66","author":"Yamada","year":"2016","journal-title":"J. Physiol. Sci."},{"key":"10.1016\/j.prp.2025.155985_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2023.154887","article-title":"Quercetin: a promising therapy for diabetic encephalopathy through inhibition of hippocampal ferroptosis","volume":"126","author":"Cheng","year":"2024","journal-title":"Phytomedicine"},{"issue":"5","key":"10.1016\/j.prp.2025.155985_bib59","doi-asserted-by":"crossref","DOI":"10.3390\/brainsci7050049","article-title":"Working memory in the prefrontal cortex","volume":"7","author":"Funahashi","year":"2017","journal-title":"Brain Sci."},{"key":"10.1016\/j.prp.2025.155985_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.nlm.2021.107463","article-title":"GLP-1R activation ameliorated novel-object recognition memory dysfunction via regulating hippocampal AMPK\/NF-\u03baB pathway in neuropathic pain mice","volume":"182","author":"Zhang","year":"2021","journal-title":"Neurobiol. Learn Mem."},{"issue":"7","key":"10.1016\/j.prp.2025.155985_bib61","article-title":"GLP-1 receptor agonists for Parkinson's disease","volume":"7","author":"Mulvaney","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.prp.2025.155985_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2021.153712","article-title":"Cascade of immune mechanism and consequences of inflammatory disorders","volume":"91","author":"Megha","year":"2021","journal-title":"Phytomedicine"},{"issue":"41","key":"10.1016\/j.prp.2025.155985_bib63","doi-asserted-by":"crossref","first-page":"62160","DOI":"10.1007\/s11356-021-16693-2","article-title":"Free radical biology in neurological manifestations: mechanisms to therapeutics interventions","volume":"29","author":"Tripathi","year":"2022","journal-title":"Environ. Sci. Pollut. Res. Int."},{"key":"10.1016\/j.prp.2025.155985_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2023.175884","article-title":"Dopamine agonists versus levodopa monotherapy in early Parkinson's disease for the potential risks of motor complications: a network meta-analysis","volume":"954","author":"Zhang","year":"2023","journal-title":"Eur. J. Pharm."},{"issue":"1","key":"10.1016\/j.prp.2025.155985_bib65","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1476-5381.2011.01687.x","article-title":"The structure and function of the glucagon-like peptide-1 receptor and its ligands","volume":"166","author":"Donnelly","year":"2012","journal-title":"Br. J. Pharm."},{"issue":"1","key":"10.1016\/j.prp.2025.155985_bib66","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41596-021-00635-w","article-title":"Engineered human blood-brain barrier microfluidic model for vascular permeability analyses","volume":"17","author":"Hajal","year":"2022","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.prp.2025.155985_bib67","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.jconrel.2017.12.015","article-title":"Crossing the blood-brain barrier with nanoparticles","volume":"270","author":"Zhou","year":"2018","journal-title":"J. Control Release"},{"issue":"8","key":"10.1016\/j.prp.2025.155985_bib68","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13081291","article-title":"Polymeric lipid hybrid nanoparticles (PLNs) as emerging drug delivery platform-a comprehensive review of their properties, preparation methods, and therapeutic applications","volume":"13","author":"Sivadasan","year":"2021","journal-title":"Pharmaceutics"},{"issue":"3","key":"10.1016\/j.prp.2025.155985_bib69","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1007\/s13346-022-01252-0","article-title":"Cell membrane-coated nanoparticles: a novel multifunctional biomimetic drug delivery system","volume":"13","author":"Liu","year":"2023","journal-title":"Drug Deliv. Transl. Res"},{"issue":"3","key":"10.1016\/j.prp.2025.155985_bib70","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1208\/s12249-025-03063-1","article-title":"Delving into nanoparticle systems for enhanced drug delivery technologies","volume":"26","author":"Abaidullah","year":"2025","journal-title":"AAPS PharmSciTech"},{"issue":"1-2","key":"10.1016\/j.prp.2025.155985_bib71","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ijpharm.2009.08.013","article-title":"Liposomal formulations of glucagon-like peptide-1: improved bioavailability and anti-diabetic effect","volume":"382","author":"Hanato","year":"2009","journal-title":"Int J. Pharm."},{"issue":"1","key":"10.1016\/j.prp.2025.155985_bib72","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s12951-025-03252-x","article-title":"Metal-organic framework-based smart stimuli-responsive drug delivery systems for cancer therapy: advances, challenges, and future perspectives","volume":"23","author":"Guo","year":"2025","journal-title":"J. Nanobiotechnol."},{"issue":"1","key":"10.1016\/j.prp.2025.155985_bib73","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.drudis.2014.09.017","article-title":"Therapeutic applications of the cell-penetrating HIV-1 Tat peptide","volume":"20","author":"Rizzuti","year":"2015","journal-title":"Drug Discov. Today"},{"issue":"1","key":"10.1016\/j.prp.2025.155985_bib74","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41392-020-00435-w","article-title":"G protein-coupled receptors: structure- and function-based drug discovery","volume":"6","author":"Yang","year":"2021","journal-title":"Signal Transduct. Target Ther."},{"issue":"1","key":"10.1016\/j.prp.2025.155985_bib75","doi-asserted-by":"crossref","first-page":"8447","DOI":"10.1038\/s41598-019-44591-8","article-title":"Combined Amylin\/GLP-1 pharmacotherapy to promote and sustain long-lasting weight loss","volume":"9","author":"Liberini","year":"2019","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.prp.2025.155985_bib76","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-023-01509-2","article-title":"The promise and challenges of combination therapies with antibody-drug conjugates in solid tumors","volume":"17","author":"Wei","year":"2024","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.prp.2025.155985_bib77","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/MED.0000000000000217","article-title":"Glucagon-like peptide-1 and gastric inhibitory polypeptide: new advances","volume":"23","author":"Gallwitz","year":"2016","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"issue":"6","key":"10.1016\/j.prp.2025.155985_bib78","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.tem.2020.02.006","article-title":"How may GIP enhance the therapeutic efficacy of GLP-1?","volume":"31","author":"Samms","year":"2020","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1016\/j.prp.2025.155985_bib79","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.674704","article-title":"Benefits of sustained upregulated unimolecular GLP-1 and CCK receptor signalling in obesity-diabetes","volume":"12","author":"Tanday","year":"2021","journal-title":"Front Endocrinol. (Lausanne)"},{"issue":"6","key":"10.1016\/j.prp.2025.155985_bib80","doi-asserted-by":"crossref","DOI":"10.3390\/ph16060836","article-title":"Multifaceted roles of GLP-1 and its analogs: a review on molecular mechanisms with a cardiotherapeutic perspective","volume":"16","author":"Pandey","year":"2023","journal-title":"Pharmaceuticals"},{"issue":"4","key":"10.1016\/j.prp.2025.155985_bib81","doi-asserted-by":"crossref","first-page":"277","DOI":"10.15430\/JCP.2013.18.4.277","article-title":"Recent advances in in vivo genotoxicity testing: prediction of carcinogenic potential using comet and micronucleus assay in animal models","volume":"18","author":"Kang","year":"2013","journal-title":"J. Cancer Prev."},{"issue":"2","key":"10.1016\/j.prp.2025.155985_bib82","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.reprotox.2006.03.012","article-title":"Critical aspects in reproductive and developmental toxicity testing of environmental chemicals","volume":"22","author":"Buschmann","year":"2006","journal-title":"Reprod. Toxicol."},{"issue":"22","key":"10.1016\/j.prp.2025.155985_bib83","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.2174\/1381612825666190722100504","article-title":"Polyphenols regulate endothelial functions and reduce the risk of cardiovascular disease","volume":"25","author":"Yamagata","year":"2019","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.prp.2025.155985_bib84","doi-asserted-by":"crossref","DOI":"10.1016\/j.psyneuen.2025.107415","article-title":"The effect of GLP-1RAs on mental health and psychotropics-induced metabolic disorders: a systematic review","volume":"176","author":"Breit","year":"2025","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.prp.2025.155985_bib85","doi-asserted-by":"crossref","first-page":"1525623","DOI":"10.3389\/fimmu.2025.1525623","article-title":"The immunomodulatory effects of GLP-1 receptor agonists in neurogenerative diseases and ischemic stroke treatment","volume":"16","author":"Sun","year":"2025","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.prp.2025.155985_bib86","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/dom.14500","article-title":"Understanding the place for GLP-1RA therapy: translating guidelines for treatment of type 2 diabetes into everyday clinical practice and patient selection","volume":"23","author":"Andreasen","year":"2021","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.prp.2025.155985_bib87","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2023.114862","article-title":"Long-acting parenteral drug delivery systems for the treatment of chronic diseases","volume":"198","author":"Jindal","year":"2023","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.prp.2025.155985_bib88","doi-asserted-by":"crossref","first-page":"420","DOI":"10.3389\/fphar.2020.00420","article-title":"Precision dosing priority criteria: drug, disease, and patient population variables","volume":"11","author":"Tyson","year":"2020","journal-title":"Front Pharm."},{"issue":"3","key":"10.1016\/j.prp.2025.155985_bib89","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1002\/bimj.201400244","article-title":"Optimal individualized dosing strategies: a pharmacologic approach to developing dynamic treatment regimens for continuous-valued treatments","volume":"58","author":"Rich","year":"2016","journal-title":"Biom. J."},{"issue":"1","key":"10.1016\/j.prp.2025.155985_bib90","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s12933-023-01798-4","article-title":"Combining glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus (T2DM)","volume":"22","author":"Gourdy","year":"2023","journal-title":"Cardiovasc Diabetol."},{"key":"10.1016\/j.prp.2025.155985_bib91","doi-asserted-by":"crossref","first-page":"12539","DOI":"10.2147\/OTT.S273866","article-title":"Effect of dose adjustments on the safety and efficacy of Afatinib in chinese patients with EGFR-mutated non-small cell lung cancer who participated in the LUX-lung clinical trial program","volume":"13","author":"Tu","year":"2020","journal-title":"Oncol. Targets Ther."},{"key":"10.1016\/j.prp.2025.155985_bib92","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2021.108843","article-title":"Comparison betweeen dapagliflozin add-on therapy and insulin dose escalation in patients with uncontrolled type 2 diabetes treated with insulin: DVI study","volume":"175","author":"Shin","year":"2021","journal-title":"Diabetes Res Clin. Pr."},{"issue":"1","key":"10.1016\/j.prp.2025.155985_bib93","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1007\/s11096-015-0210-4","article-title":"Pharmaceutical care of elderly patients with poorly controlled type 2 diabetes mellitus: a randomized controlled trial","volume":"38","author":"Chen","year":"2016","journal-title":"Int. J. Clin. Pharm."},{"key":"10.1016\/j.prp.2025.155985_bib94","doi-asserted-by":"crossref","DOI":"10.1177\/10732748241244586","article-title":"A systematic review of treatment-related adverse events for combination therapy of multiple tyrosine kinase inhibitor and immune checkpoint inhibitor","volume":"31","author":"Sawada","year":"2024","journal-title":"Cancer Control"},{"issue":"10","key":"10.1016\/j.prp.2025.155985_bib95","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/nrendo.2016.86","article-title":"Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus","volume":"12","author":"Tahrani","year":"2016","journal-title":"Nat. Rev. Endocrinol."},{"issue":"5","key":"10.1016\/j.prp.2025.155985_bib96","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.2174\/1570159X21666230216101659","article-title":"Selecting the best animal model of Parkinson's disease for your research purpose: insight from in vivo PET imaging studies","volume":"21","author":"Real","year":"2023","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.prp.2025.155985_bib97","series-title":"Animal Models of Parkinson\u2019s Disease, in Parkinson\u2019s Disease: Pathogenesis and Clinical Aspects","author":"Konnova","year":"2018"},{"issue":"4","key":"10.1016\/j.prp.2025.155985_bib98","first-page":"422","article-title":"MPTP-induced mouse model of Parkinson's disease: a promising direction of therapeutic strategies","volume":"21","author":"Mustapha","year":"2021","journal-title":"Bosn. J. Basic Med Sci."},{"key":"10.1016\/j.prp.2025.155985_bib99","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.biopha.2018.08.088","article-title":"Recent updates on GLP-1 agonists: current advancements & challenges","volume":"108","author":"Sharma","year":"2018","journal-title":"Biomed. Pharm."},{"issue":"10","key":"10.1016\/j.prp.2025.155985_bib100","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19102926","article-title":"Molecular biomarkers for gestational diabetes mellitus","volume":"19","author":"Dias","year":"2018","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.prp.2025.155985_bib101","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2021.645996","article-title":"Biomarkers and the role of \u03b1-synuclein in Parkinson's disease","volume":"13","author":"Du","year":"2021","journal-title":"Front Aging Neurosci."},{"issue":"2","key":"10.1016\/j.prp.2025.155985_bib102","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1590\/s1806-37562018000000088","article-title":"Inclusion and exclusion criteria in research studies: definitions and why they matter","volume":"44","author":"Patino","year":"2018","journal-title":"J. Bras. Pneumol."},{"issue":"2","key":"10.1016\/j.prp.2025.155985_bib103","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s10815-024-03342-z","article-title":"Interacting and joint effects of assisted reproductive technology and gestational diabetes mellitus on preterm birth and the mediating role of gestational diabetes mellitus: a cohort study using a propensity score","volume":"42","author":"Xiang","year":"2025","journal-title":"J. Assist Reprod. Genet."},{"key":"10.1016\/j.prp.2025.155985_bib104","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/978-1-0716-3499-8_12","article-title":"The basics of visualizing, analyzing, and reporting preclinical PET\/CT imaging data","volume":"2729","author":"Cawthorne","year":"2024","journal-title":"Methods Mol. Biol."},{"issue":"7","key":"10.1016\/j.prp.2025.155985_bib105","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25073812","article-title":"GLP-1 receptor agonists: a new treatment in Parkinson's disease","volume":"25","author":"Kalinderi","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.prp.2025.155985_bib106","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/00041327-200303000-00009","article-title":"Positron emission tomography (PET) and single photon emission computed tomography (SPECT): clinical applications","volume":"23","author":"Blake","year":"2003","journal-title":"J. Neuroophthalmol."},{"issue":"4","key":"10.1016\/j.prp.2025.155985_bib107","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2165\/00063030-200822040-00004","article-title":"Long-acting GLP-1 analogs for the treatment of type 2 diabetes mellitus","volume":"22","author":"Vilsb\u00f8ll","year":"2008","journal-title":"BioDrugs"},{"key":"10.1016\/j.prp.2025.155985_bib108","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.envint.2018.04.034","article-title":"Long term exposure to air pollution and mortality in an elderly cohort in Hong Kong","volume":"117","author":"Yang","year":"2018","journal-title":"Environ. Int"},{"issue":"9","key":"10.1016\/j.prp.2025.155985_bib109","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-012555","article-title":"Evidence-based interventions to reduce adverse events in hospitals: a systematic review of systematic reviews","volume":"6","author":"Zegers","year":"2016","journal-title":"BMJ Open"},{"issue":"5","key":"10.1016\/j.prp.2025.155985_bib110","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1177\/10915818241255885","article-title":"Exploring greater flexibility for chronic toxicity study designs to support human safety assessment while balancing 3Rs considerations","volume":"43","author":"Prior","year":"2024","journal-title":"Int J. Toxicol."},{"key":"10.1016\/j.prp.2025.155985_bib111","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/164_2020_403","article-title":"Drug delivery strategies to overcome the blood-brain barrier (BBB)","volume":"273","author":"Helms","year":"2022","journal-title":"Handb. Exp. Pharm."},{"issue":"1","key":"10.1016\/j.prp.2025.155985_bib112","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1186\/s12913-025-12541-y","article-title":"Adopting and adapting foreign innovations in health service delivery: a case study in elderly care in Suzhou, China","volume":"25","author":"Wang","year":"2025","journal-title":"BMC Health Serv. Res"},{"issue":"6","key":"10.1016\/j.prp.2025.155985_bib113","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jalz.2016.02.010","article-title":"Neuroinflammation in Alzheimer's disease: current evidence and future directions","volume":"12","author":"Calsolaro","year":"2016","journal-title":"Alzheimers Dement"},{"issue":"1","key":"10.1016\/j.prp.2025.155985_bib114","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1186\/s13098-024-01448-z","article-title":"Causal relationships between GLP1 receptor agonists, blood lipids, and heart failure: a drug-target mendelian randomization and mediation analysis","volume":"16","author":"Mao","year":"2024","journal-title":"Diabetol. Metab. Syndr."},{"issue":"24","key":"10.1016\/j.prp.2025.155985_bib115","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1161\/CIRCULATIONAHA.122.059595","article-title":"GLP-1 receptor agonists for the reduction of atherosclerotic cardiovascular risk in patients with type 2 diabetes","volume":"146","author":"Marx","year":"2022","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.prp.2025.155985_bib116","doi-asserted-by":"crossref","first-page":"729","DOI":"10.21037\/atm-20-4354","article-title":"Non-alcoholic fatty liver disease (NAFLD)\/non-alcoholic steatohepatitis (NASH)-related liver fibrosis: mechanisms, treatment and prevention","volume":"9","author":"Tacke","year":"2021","journal-title":"Ann. Transl. Med"},{"issue":"7","key":"10.1016\/j.prp.2025.155985_bib117","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1007\/s00125-021-05442-2","article-title":"Liver-targeting drugs and their effect on blood glucose and hepatic lipids","volume":"64","author":"Gastaldelli","year":"2021","journal-title":"Diabetologia"},{"key":"10.1016\/j.prp.2025.155985_bib118","doi-asserted-by":"crossref","first-page":"1416403","DOI":"10.3389\/fphar.2024.1416403","article-title":"The signaling pathways of selected traditional Chinese medicine prescriptions and their metabolites in the treatment of diabetic cardiomyopathy: a review","volume":"15","author":"Li","year":"2024","journal-title":"Front Pharm."},{"issue":"11","key":"10.1016\/j.prp.2025.155985_bib119","doi-asserted-by":"crossref","DOI":"10.3390\/brainsci13111503","article-title":"GLP-1 receptor agonists and related mental health issues; insights from a range of social media platforms using a mixed-methods approach","volume":"13","author":"Arillotta","year":"2023","journal-title":"Brain Sci."},{"issue":"5","key":"10.1016\/j.prp.2025.155985_bib120","doi-asserted-by":"crossref","DOI":"10.3390\/md19050251","article-title":"Anti-Alzheimer's molecules derived from marine life: understanding molecular mechanisms and therapeutic potential","volume":"19","author":"Kabir","year":"2021","journal-title":"Mar. Drugs"},{"issue":"1","key":"10.1016\/j.prp.2025.155985_bib121","first-page":"48","article-title":"TGF-\u03b21 mediates hypoxia-preconditioned olfactory mucosa mesenchymal stem cells improved neural functional recovery in Parkinson's disease models and patients","volume":"11","author":"Zhuo","year":"2024","journal-title":"Mil. Med. Res."},{"key":"10.1016\/j.prp.2025.155985_bib122","doi-asserted-by":"crossref","first-page":"1431292","DOI":"10.3389\/fendo.2024.1431292","article-title":"Mechanisms of action and therapeutic applications of GLP-1 and dual GIP\/GLP-1 receptor agonists","volume":"15","author":"Liu","year":"2024","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.prp.2025.155985_bib123","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.114083","article-title":"Clinical translation of nanomedicines: challenges, opportunities, and keys","volume":"181","author":"Younis","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"4","key":"10.1016\/j.prp.2025.155985_bib124","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/j.1365-2125.2006.02596.x","article-title":"Monitoring for adverse drug reactions","volume":"61","author":"Coleman","year":"2006","journal-title":"Br. J. Clin. Pharm."},{"issue":"6","key":"10.1016\/j.prp.2025.155985_bib125","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e17488","article-title":"Advances in drug delivery systems, challenges and future directions","volume":"9","author":"Ezike","year":"2023","journal-title":"Heliyon"},{"issue":"1","key":"10.1016\/j.prp.2025.155985_bib126","first-page":"47","article-title":"Light-based approaches to cardiac Arrhythmia research: from basic science to translational applications","volume":"10","author":"Karathanos","year":"2016","journal-title":"Clin. Med. Insights Cardiol."}],"container-title":["Pathology - Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033825001773?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033825001773?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T14:35:22Z","timestamp":1747406122000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0344033825001773"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":126,"alternative-id":["S0344033825001773"],"URL":"https:\/\/doi.org\/10.1016\/j.prp.2025.155985","relation":{},"ISSN":["0344-0338"],"issn-type":[{"value":"0344-0338","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The critical role of GLP-1 signaling pathways in the pathology of Parkinson's disease and diabetes","name":"articletitle","label":"Article Title"},{"value":"Pathology - Research and Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prp.2025.155985","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier GmbH. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"155985"}}